In-stent stenosis: pathology and implications for the development of drug eluting stents.
Bennett
Martin R
MR
Addenbrooke's Centre for Clinical Investigation, Box 110, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK. mrb@mole.bio.cam.ac.uk
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D001918:Brachytherapy / Q000379:methods; D023903:Coronary Restenosis / Q000473:pathology / Q000517:prevention & control*; D004343:Drug Implants / Q000009:adverse effects; D006083:Graft Occlusion, Vascular / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D020123:Sirolimus / Q000008:administration & dosage; D015607:Stents
D020533:Angiogenesis Inhibitors; D004343:Drug Implants; D007166:Immunosuppressive Agents; D017239:Paclitaxel; D020123:Sirolimus